Last mentioned: Mar 16, 2026
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
Urgent warnings have been issued across 26 major outlets regarding dietary supplements sold on Amazon that were found to contain poisonous substances. The discovery of toxic contaminants in third-party products has reignited the debate over e-commerce liability and the safety of the largely unregulated supplement market.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
This page surfaces every story mentioning FDA across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |